Clinical trials: Neoadjuvant Immunochemotherapy
Non-Small Cell Lung Cancer
Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC
Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting, there is still a lack of valid data for operable NSCLC in the real world.
- Trial name
- NeoR-World (NCT05974007)
- Testing
- Neoadjuvant immunochemotherapy, Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences